MedTrace Logo

The Effects of Glimepiride in Patients With Type 2 Diabetes and Chronic Heart Failure

NCT05538819 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1018

Last updated 2022-11-16

No results posted yet for this study

Summary

Thirty years ago, Dzau and Braunwald introduced the concept of a continuum of cardiovascular diseases and defined them as a series of events caused by numerous related and unrelated risk factors, thus developing to end-stage heart disease through many pathophysiological pathways and processes. Owing to treatment concept changes and the urgency of investigating T2D combined with CHF, SUs are being re-evaluated, of which glimepiride is undoubtedly the most promising.

Conditions

Interventions

DRUG

Glimepiride

Glimepiride 1-4 mg/day

Sponsors & Collaborators

  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences

    collaborator OTHER

  • Dao Wen Wang

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2022-06-01
Completion
2022-07-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05538819 on ClinicalTrials.gov